Sonoma Pharmaceuticals Inc (SNOA) - Total Assets
Based on the latest financial reports, Sonoma Pharmaceuticals Inc (SNOA) holds total assets worth $18.11 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sonoma Pharmaceuticals Inc - Total Assets Trend (2002–2026)
This chart illustrates how Sonoma Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see SNOA stock market capitalisation for the company's overall valuation and market capitalisation.
Sonoma Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (March 2026)
Sonoma Pharmaceuticals Inc's total assets of $18.11 Million consist of 86.7% current assets and 13.3% non-current assets. Review SNOA current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.2% |
| Accounts Receivable | $5.43 Million | 38.9% |
| Inventory | $3.65 Million | 26.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2002–2026)
This chart illustrates how Sonoma Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Sonoma Pharmaceuticals Inc stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sonoma Pharmaceuticals Inc's current assets represent 86.7% of total assets in 2026, an increase from 45.3% in 2002.
- Cash Position: Cash and equivalents constituted 17.2% of total assets in 2026, down from 45.3% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2002.
- Asset Diversification: The largest asset category is accounts receivable at 38.9% of total assets.
Sonoma Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Sonoma Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Sonoma Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.99 | 2.70 | 4.42 |
| Quick Ratio | 2.29 | 1.92 | 3.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $10.82 Million | $8.26 Million | $13.94 Million |
Sonoma Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Sonoma Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.96 |
| Latest Market Cap to Assets Ratio | 0.43 |
| Asset Growth Rate (YoY) | 1.9% |
| Total Assets | $13.96 Million |
| Market Capitalization | $6.03 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sonoma Pharmaceuticals Inc's assets below their book value (0.43x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Sonoma Pharmaceuticals Inc's assets grew by 1.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Sonoma Pharmaceuticals Inc (2002–2026)
The table below shows the annual total assets of Sonoma Pharmaceuticals Inc from 2002 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | $13.96 Million | +1.95% |
| 2025-03-31 | $13.69 Million | -7.10% |
| 2024-03-31 | $14.74 Million | -9.19% |
| 2023-03-31 | $16.23 Million | -13.87% |
| 2022-03-31 | $18.84 Million | +25.74% |
| 2021-03-31 | $14.99 Million | +2.93% |
| 2020-03-31 | $14.56 Million | +0.78% |
| 2019-03-31 | $14.45 Million | -24.77% |
| 2018-03-31 | $19.21 Million | -24.56% |
| 2017-03-31 | $25.46 Million | +84.45% |
| 2016-03-31 | $13.80 Million | -8.27% |
| 2015-03-31 | $15.05 Million | -27.62% |
| 2014-03-31 | $20.79 Million | +65.47% |
| 2013-03-31 | $12.56 Million | +60.31% |
| 2012-03-31 | $7.84 Million | -9.53% |
| 2011-03-31 | $8.66 Million | -15.21% |
| 2010-03-31 | $10.22 Million | +87.59% |
| 2009-03-31 | $5.45 Million | -76.93% |
| 2008-03-31 | $23.61 Million | -12.39% |
| 2007-03-31 | $26.95 Million | +112.39% |
| 2006-03-31 | $12.69 Million | +82.84% |
| 2005-03-31 | $6.94 Million | +622.16% |
| 2003-03-31 | $961.00K | -43.03% |
| 2002-03-31 | $1.69 Million | -- |
About Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin f… Read more